ImaginAb Enrolls First Patient in Phase II Clinical Trial
LOS ANGELES, Jan. 18, 2019 /PRNewswire/ -- ImaginAb, Inc., an emerging immuno-oncology imaging company, announced today the enrollment of the first patient in the Phase II clinical trial of ImaginAb's CD8+ T Cell imaging agent. The trial will enroll metastatic cancer patients and will study the correlation of imaging signals observed using ImaginAb's CD8+ T cell Immuno-PET imaging agent, standard-of-care scans, and immunohistochemistry analysis of CD8 in biopsied tissues. The trial will also measure changes in CD8+ T-cell distribution before and after immuno-oncology therapies. The study is, in part, financially supported by Boehringer Ingelheim and contributes to the aims of the strategic collaboration between ImaginAb and Boehringer Ingelheim to develop ImaginAb's CD8+ T cell Immuno-PET imaging agent, IAB22M2C.
IAB22M2C is designed to be used with PET scan technology to non-invasively measure CD8+ T cell tumor infiltrates in patients with cancer, including the identification of changes in CD8+ T cell tumor infiltrates induced by immuno-oncology treatments. This investigational approach has the potential to guide the development of immunomodulatory agents and combinations by assessing whether a patient's immune system responds to such agents, thereby offering an early prediction of therapeutic response.
"This study is following on the heels of our recently completed Phase I study which showed an excellent safety profile and extremely encouraging preliminary efficacy of our CD8+ T cell Immuno-PET imaging tracer," said Martyn Coombs, CEO of ImaginAb. "We are thrilled to be continuing our collaboration with Boehringer Ingelheim and are looking forward to Phase II data. We have now announced three CD8+ clinical collaborations with pharmaceutical companies, including our collaborations with Nektar Therapeutics and Merck, known as MSD outside the United States and Canada. This progress underscores our belief that our platform has the potential to accelerate clinical development of therapies for cancer patients. We anticipate announcing more collaborations in the near future."
ImaginAb, Inc. is an emerging immuno-oncology company focused on providing actionable insight into patient selection and treatment progress for cancer immunotherapy, enabling precision medicine. ImaginAb engineers antibody fragments called minibodies that maintain the exquisite specificity of full-length antibodies while remaining inert in the body. Used with widely available PET scan technology, these novel minibodies illuminate high-value molecular targets, providing physicians with a whole-body picture of immune activity. ImaginAb is also advancing a best-in-class imaging agent to improve prostate cancer management and patient outcomes, as well as developing a pipeline for other targets in oncology. ImaginAb's products have the potential to improve patient care and lower healthcare costs.
For more information about ImaginAb's pipeline and technology, visit www.imaginab.com.